List of Tables
Table 3.1 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 4.1 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 4.2 Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2024-2029
Table 4.3 Patent Status of Selected Leading Biologics
Table 4.4 Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2019-2024
Table 4.5 Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 5.1 First Approvals for Recombinant Protein Therapies,1982-1993
Table 5.2 Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.3 Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2024-2029
Table 5.4 Diabetes Prevalence in Leading National Markets, 2017
Table 5.5 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.6 Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2024-2029
Table 5.7 Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.8 Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2024-2029
Table 5.9 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.10 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2024-2029
Table 5.11 Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.12 Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%),2024-2029
Table 5.13 Selected Insulin Biosimilars which have been Approved and Launched
Table 5.14 Selected EPO Biosimilars Approved in India
Table 5.15 European Biosimilar Approvals: G-CSF
Table 5.16 Selected Filgrastim Biosimilars Approved Worldwide
Table 5.17 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.18 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 5.19 Selected Coagulating Factors Significant in Segment
Table 5.20 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.21 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2024-2029
Table 5.22 Selected Approved Branded Interferon Therapies
Table 5.23 Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.24 Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019 to 2029
Table 5.25 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2024
Table 5.26 Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2024-2029
Table 5.27 Selected Interferon Alfa Biosimilars Approved Worldwide, 2016-2018
Table 5.28 Selected Interferon Beta Biosimilars Approved Worldwide, 2016-2018
Table 5.29 Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.30 Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2024-2029
Table 5.31 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2024
Table 5.32 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%),2024-2029
Table 6.1 Regions of an Antibody
Table 6.2 Natural Antibody Mechanisms of Action
Table 6.3 Selected Biosimilar Adalimumab Candidates
Table 6.4 Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 6.5 Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 6.6 Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 6.7 Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2024-2029
Table 6.8 Stelara Revenue 2016-2018:
Revenues ($bn), AGR (%)
Table 6.9 Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 6.10 Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 6.11 Xolair Revenue Breakdown (between Roche and Novartis): Revenue ($bn), AGR (%), 2017-2018
Table 6.12 Selected Ongoing Lebrikizumab Clinical Trials
Table 6.13 Selected Ongoing Anifrolumab Clinical Trials
Table 6.14 Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2019-2024
Table 6.15 Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2024-2029
Table 6.16 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2019-2024
Table 6.17 Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2024-2029
Table 6.18 Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 6.19 Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 6.20 FDA-Approved Indications for Cyramza
Table 6.21 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 6.22 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 7.1 Amgen’s US Patents and Expiry Dates for Enbrel
Table 7.2 Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 7.3 Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2024-2029
Table 7.4 Eylea Revenue Breakdown 2017-2018: Regeneron and Bayer
Table 7.5 Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 7.6 Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 7.7 Bristol-Myers Squibb’s pipeline developments for Orencia
Table 7.8 Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 7.9 Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 8.1 Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 8.2 Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 8.3 Potency and Source of Stem Cells
Table 8.4 Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 8.5 Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 8.6 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2024
Table 8.7 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2024-2029
Table 8.8 Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 8.9 Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 8.10 Apligraf Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 8.11 Apligraf Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 8.12 Dermagraft Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2024
Table 8.13 Dermagraft Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2024-2029
Table 8.13 IMLYGICRevenue Forecast: Revenue ($bn), AGR (%), CAGR (%),2019-2024
Table 8.14 IMLYGICRevenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 9.1 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2019-2024
Table 9.2 Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 9.3 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share(%), 2019-2024
Table 9.4 US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 9.5 European Biosimilar Approvals, 2006-2018
Table 9.6 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2019-2024
Table 9.7 EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2024-2029
Table 9.8 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2019-2024
Table 9.9 Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 9.10 BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2019-2024
Table 9.11 BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2024-2029
Table 11.1 AbbVie, Inc.: Profile
Table 11.2 AbbVie, Inc.: Key Developments
Table 11.3 Amgen: Profile
Table
Table 11.4 Amgen: Key Developments
Table 11.5 AstraZeneca PLC: Profile
Table 11.6 AstraZeneca PLC: Key Developments
Table 11.7 Bayer AG: Profile
Table 11.8 Bayer AG: Key Developments
Table 11.9 Eli Lilly: Profile
Table 11.10 Eli Lilly: Key Developments
Table 11.11 Roche: Profile
Table 11.12 Roche: Key Developments
Table 11.13 GSK: Profile
Table 11.14 GlaxoSmithKline Plc.: Profile
Table 11.15 Johnson & Johnson: Profile
Table 11.16 Johnson & Johnson: Profile
Table 11.17 Merck & Co., Inc.: Profile
Table 11.18 Merck & Co., Inc.: Key Developments
Table 11.19 Novartis: Profile
Table 11.20 Novartis: Key Developments
Table 11.21 Pfizer: Profile
Table 11.22 Pfizer: Key Developments
Table 11.23 Sanofi: Profile
Table 11.24 Sanofi: Key Developments
Table 11.25 Novo Nordisk A/S: Profile
Table 11.26 Novo Nordisk A/S: Key Developments
Table 11.27 Takeda Pharmaceutical Company Limited: Profile
Table 11.28 Takeda Pharmaceutical Company Limited: Key Developments
Table 11.29 Gilead Sciences Inc.,: Profile
Table 11.30 Gilead Sciences Inc.,: Key Developments
Table 11.31 Alexion Pharmaceuticals, Inc.,: Profile
Table 11.32 Alexion Pharmaceuticals, Inc.,: Key Developments
Table 11.33 Samsung Biologics: Profile
Table 11.34 Samsung Biologics: Key Developments
Table 11.35 UCB SA: Profile
Table 11.36 UCB SA: Key Developments
Table 11.37 Celgene Corporation: Profile
Table 11.38 Celgene Corporation: Key Developments
Table 11.37 Precision Biologics, Inc.: Profile

List of Figures
Figure 1.1 Forecasted Submarkets of the Biologics Market
Figure 4.1 Global Biologics Market Forecast: Revenues ($bn), 2019 - 2029
Figure 4.2 Submarkets within the Biologics Market Forecast: Revenues ($bn), 2018-2029
Figure 5.1 Protein Therapeutics Submarket Forecast: Revenues ($bn), 2019 - 202
Figure 5.2 Diabetes Prevalence in Leading National Markets, 2018
Figure 5.3 Insulin Submarket Forecast: Revenues ($bn), 2019 - 2029
Figure 5.4 Lantus Revenue Forecast: Revenues ($bn), 2019 - 2029
Figure 5.5 NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), 2019 - 2029
Figure 5.6 Humalog Revenue Forecast: Revenues ($bn), 2019 - 2029
Figure 5.7 Other Recombinant Hormones Submarket Forecast: Revenues ($bn), 2019 - 2029
Figure 5.8 Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), 2019 - 2029
Figure 5.9 Avonex Submarket Forecast: Revenues ($bn), 2019 - 2029
Figure 5.10 Rebif Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 5.11 Interferon Submarket Forecast: Revenues ($bn), 2019 - 2029
Figure 5.12 Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), 2019 - 2029
Figure 6.1 Humira Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 6.2 Remicade Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 6.3 Stelara Revenue 2016-2018, Revenue ($bn)
Figure 6.4 Tysabri Revenue Forecast: Revenue ($m), 2019 - 2029
Figure 6.5 Herceptin Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 6.6 Kadcyla Revenue Forecast: Revenue ($m), 2018 -2029
Figure 6.7 Perjeta Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 6.8 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), 2019 - 2029
Figure 7.1 Enbrel Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 7.2 Eylea Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 7.3 Fusion Proteins Forecast: Revenue ($bn), 2019 - 2029
Figure 8.1 Regenerative Medicines Market Forecast: Revenue ($bn), 2019 - 2029
Figure 8.2 Osteocel Plus Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 8.3 Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), 2019 - 2029
Figure 8.4 Stem Cell Therapies Market Forecast: Revenue ($bn), 2019 - 2029
Figure 8.5 Apligraf Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 8.6 Dermagraft Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 8.7 IMLYGIC Revenue Forecast: Revenue ($bn), 2019 - 2029
Figure 9.1 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2018
Figure 9.2 Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2029
Figure 9.3 Regional Forecasts for Global Biologics Market: Revenues ($bn) 2019 - 2029
Figure 9.4 US Biologics Market: Revenues ($bn), 2019 - 2029
Figure 9.5 EU5 Market Breakdown: Market Share (%), 2018
Figure 9.6 EU5 Biologics Market: Revenues ($bn), 2019 - 2029
Figure 9.7 Japanese Biologics Market: Revenues ($bn), 2019 - 2029
Figure 9.8 Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2018
Figure 9.9 BRIC Biologics Market: Revenues ($bn), 2019 - 2029
Figure 9.10 Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2029
Figure 10.1 SWOT Analysis of Biologics Market and Industry
Figure 10.2 STEP Analysis of Biologics Market and Industry
Figure 12.1 Global Biologics Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2019 - 2029